EPISODE · Nov 30, 2023 · 6 MIN

Key Points from the Adaura Trial: Osimertinib

from GRACEcast - Discussions with the Global Resource for Advancing Cancer Education · host cancerGRACE

Dr. Joshua Reuss examines important details learned during the ADAURA trial, including overall survival, reduced risk of brain mets, and side effects.

Episode metadata supplied by the publisher feed · Published Nov 30, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Key Points from the Adaura Trial: Osimertinib

0:00 6:14

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of GRACEcast - Discussions with the Global Resource for Advancing Cancer Education?

This episode is 6 minutes long.

When was this GRACEcast - Discussions with the Global Resource for Advancing Cancer Education episode published?

This episode was published on November 30, 2023.

Can I download this GRACEcast - Discussions with the Global Resource for Advancing Cancer Education episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!